Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors Recruiting

2024-516870-31-00 Endometrial Carcinoma 2025-07-11
Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies Recruiting

2024-515687-31-01 Patients suffering from cancer without further treatmen 2025-07-09
Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safe… Recruiting

2024-517644-62-00 Mild to Moderate Asthma 2025-06-30
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants with Systemic Lupus Ery… Recruiting

2024-519015-34-00 Systemic Lupus Erythematosus 2025-06-30
First in human, Phase 1a/1b Study of KM-023 in healthy volunteers and Olmsted syndrome patients Recruiting

2025-521446-20-00 Olmsted syndrome 2025-06-27
Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell… Recruiting

2024-519318-30-00 non-Hodgkin Lymphomas Subtypes: DLBCL - ORPHA: 544 Ag 2025-06-25
A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignanci… Recruiting

2024-516838-35-00 Patients with relapsed/refractory Lymphoma or ALL aged 2025-06-23
A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy ad… Recruiting

2024-519328-26-01 Sexual Transmitted Infection (STI) 2025-06-18
A First-in-Human phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-2… Recruiting

2024-518360-13-00 HER2-positive metastatic breast cancer 2025-06-18
To investigate the safety and efficacy of a novel investigational compound against neurological diseases such as Parkinson's disease in heal… Recruiting

2025-521357-17-00 Parkinson's disease 2025-06-13
A phase I study to evaluate the safety and preliminary signs of efficacy of [177Lu]Lu-OncoFAP-23 alone and in combination with L19-IL2 as a … Recruiting

2023-509453-31-00 Patients with advanced/metastatic FAP-positive tumors 2025-06-11
A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients with C3-Glomerulopathy Recruiting

2024-517992-19-00 C3 glomerulopathy (C3G) 2025-06-11
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neopla… Recruiting

2024-514341-10-00 Relapsed or Refractory Acute Myeloid Leukemia or Relaps 2025-05-27
A clinical study of the V540C vaccine in healthy adults (V540C-003) Recruiting

2024-518863-36-00 Human Papilloma virus 2025-05-27
Randomized, Double Blind, Placebo Controlled "first-in-human" Study to Assess the Safety and Tolerability of Single Ascending Intravenous Do… Recruiting

2023-504324-26-00 Prevention of infections caused by Gram-negative bacter 2025-05-20
A first-in-human study to learn about the safety of BAY 3547926 and how well it works in participants with advanced liver cancer Recruiting

2024-516615-25-00 hepatocellular carcinoma (HCC) 2025-05-14
A Study of LY4057996 in Healthy Participants and Participants with Type 1 and Type 2 Diabetes (YKAA) Recruiting

2024-519151-28-00 Healthy, Diabetes Mellitus, Type 1 Diabetes Mellitus, T 2025-05-14
A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria. Recruiting

2024-516911-26-00 Malaria 2025-05-07
FusionVAC22_02: DNAJB1-PRKACA fusion transcript-based peptide vaccine for fibrolamellar hepatocellular carcinoma patients and other tumor en… Recruiting

2024-519387-41-00 tumor entities carrying the oncogenic driver fusion 2025-05-07
Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs). Recruiting

2024-511915-21-01 advanced or metastasic triple-negative breast cancer 2025-05-05
Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer? Recruiting

2024-511435-10-00 Hepatocellular Carcinoma 2025-04-30
A First-in-Human Study to Test the Safety and Effects of the Investigational Drug IPH4502 in People with Advanced Cancers Recruiting

2024-519162-46-00 Advanced Solid Tumors 2025-04-25
First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors Recruiting

2024-512058-11-00 Advanced Solid Tumor 2025-04-09
A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors Recruiting

2024-512019-36-00 Adrenocortical carcinoma 2025-04-09